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Abstract
Despite significant advances in revascularization techniques and medical therapy, there re-
mains a significant population of patients who continue to have intractable angina symptoms.
This review aims to define the patients with refractory angina pectoris (RAP) and to present
the therapeutic options currently available for this condition.
RAP itself is defined and the pharmacological treatment options other than traditional medical
therapies are discussed. The latest therapeutic options for this patient population are exten-
sively reviewed. Among the multitude of pharmacological and non-invasive therapeutic op-
tions for patients with RAP, ranolazine is a new drug indicated for the treatment of chronic
angina, in combination with amlodipine, beta-blockers or nitrates. Enhanced external coun-
terpulsation has not only been shown to improve symptoms, but also to improve long-term
ventricular function in these patients. In randomized trials, neurostimulation has been shown
to be effective in reducing angina symptoms. Transmyocardial laser revascularization has
emerged as an invasive treatment for RAP over the last two decades. Extracorporeal shockwave
myocardial revascularization gene therapy and percutaneous in situ coronary venous arteria-
lization are still under investigation. (Cardiol J 2011; 18, 4: 343–351)
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Introduction
Refractory angina pectoris (RAP), defined as
angina refractory to maximal medical therapy and
standard coronary revascularization procedures,
remains a significant health problem in the United
States and worldwide. Despite many recent thera-
peutic advances, patients with RAP are not ade-
quately treated.
An estimated 6.4 million patients in the Unit-
ed States suffer from symptomatic coronary artery
disease (CAD), and about 400,000 new cases deve-
lop each year [1]. Despite optimal medical therapy
and invasive procedures such as angioplasty and
cardiac bypass surgery, an estimated 300,000 to
900,000 patients in the United States have RAP, with
between 25,000 and 75,000 new cases diagnosed
each year [1]. Routine tasks such as climbing a flight
of stairs, walking a block, or dusting furniture be-
come impossible without these difficult-to-treat
patients experiencing chest pain. Many patients are
left to suffer from their symptoms, restrict their
activities chronically, and anticipate a reduced life
expectancy. Before diagnosing a patient with RAP,
repeated attempts at ‘optimizing’ medical treatment
and lifestyle modification (initiation of an exercise
program and discontinuation of tobacco) should be
made. Additionally, all secondary causes of angina,
such as anemia and uncontrolled hypertension,
should be excluded [2].
Current non-pharmacologic options for patients
with RAP include neurostimulation (transcutaneous
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electrical nerve stimulation and spinal cord stimu-
lation), enhanced external counterpulsation (EECP)
therapy, laser revascularization, gene therapy, and
newer interventional procedures such as percuta-
neous in situ coronary venous arterialization and
percutaneous in situ coronary artery bypass [2].
How to optimize medical therapy
Optimal medical therapy is well described by
the patients enrolled in the COURAGE trial and
reflects a more aggressive medical treatment than
traditional anti-anginal treatment [3]. Patients on
optimal medical therapy should receive anti-plate-
let therapy with aspirin at a dose of 81–325 mg dai-
ly, or 75 mg of clopidogrel daily if intolerant to as-
pirin. The treatment regimen should include a long-
-acting beta-blocker, a calcium channel blocker, and
isosorbide mononitrate, alone or in combination. If
tolerated, an angiotensin-converting enzyme inhibi-
tor or angiotensin receptor blockers could be add-
ed. Aggressive reduction of low-density lipoprotein
(LDL) cholesterol to a target level of 60–85 mg/dL,
using a statin alone, or in combination with
ezetimibe, should be undertaken. When the LDL
cholesterol target is achieved, an attempt should be
made to raise high-density lipoprotein (HDL) cho-
lesterol to above 40 mg/dL and to lower triglyceri-
de to below 150 mg/dL, using exercise, extended-
-release niacin (vitamin B3) or fibrates, alone or in
combination (Table 1).
New pharmacological agents
Ranolazine is a piperazine derivative anti-an-
ginal and anti-ischemic agent believed to have its
effects via alteration of the intracellular sodium le-
vel, which in turn through sodium-dependent cal-
cium channels prevents calcium overload that caus-
es cardiac ischemia [4].
It has been shown to decrease angina episodes
and improve exercise tolerance in individuals with
CAD on maximal doses of amlodipine, atenolol or dil-
tiazem. Unlike traditional anti-anginal medications
such as nitrates and beta-blockers, ranolazine does not
significantly alter either the heart rate or blood pres-
sure, and is therefore of particular interest in individ-
uals with angina refractory to maximal tolerated dos-
es of these medications. Previously, there was a con-
cern that ranolazine increased the QT interval
(approximately 2 to 6 ms) which has a theoretical
risk of causing arrhythmias (Table 2). However, the
findings of MERLIN TIMI 36 have assuaged this
concern [5]. In 6,560 post-acute coronary syndrome
non-ST elevation myocardial infarction patients, ra-
nolazine did not show significant benefit in terms
of the study’s primary endpoints of cardiovascular
death, myocardial infarction (MI), or recurrent is-
chemia at one year follow-up, but surprisingly had
a potential benefit with respect to supraventricular
(SVT) and ventricular tachycardia (VT) assessed by
Holter monitoring. In particular, patients treated
with ranolazine had fewer episodes of VT > 8 beats,
SVT, and ventricular pauses > 3 s in arrhythmia.
However, studies specifically designed to evaluate
the potential role of ranolazine as an anti-arrhyth-
mic agent are warranted.
The U.S. Food and Drug Administration (FDA)
approved ranolazine in 2002. It is indicated for the
treatment of chronic angina, in combination with am-
lodipine, beta-blockers or nitrates, in patients who do
not adequately respond to other anti-anginal drugs.
Ivabradine (Procoralan) is a member of a new
class of selective heart rate (HR)–lowering agents
that act specifically on the sinoatrial node (SAN).
Ivabradine selectively and specifically inhibits I(f),
a primary SAN pacemaker current [6], thereby re-
ducing HR at rest and during exercise in healthy
human volunteers. The safety and efficacy of ivabra-
dine for relieving angina and underlying ischemia
has been studied by Borer et al. [7] In a double-
-blind, placebo-controlled trial of 360 patients with
chronic stable angina, 10 mg of ivabradine twice
daily caused a 12% increase in the time to onset of
1-mm ST-segment depression, and a 9.5% increase
Table 1. Optimal medical therapy as defined in the COURAGE trial.
1. Aspirin 81 mg/325 mg 6. ACE inhibitor/angiotensin receptor blocker
2. Plavix 75 mg if unable to use aspirin 7. Aggressive LDL-C reduction to 65–80 mg/dL
3. Long-acting beta-blocker alone or combination therapy
4. Calcium channel blocker 8. HDL-C target to > 40 mg/dL
(dihydropyridine class) 9. TG target level to < 150 mg/dL
5. Nitrates
ACE — angiotensin converting enzyme; HDL-C — high density lipoprotein cholesterol; LDL-C — low density lipoprotein cholesterol; TG — triglyceride
} With exercise, niacin,fibrates or combination
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in exercise tolerance. Additionally, the use of iva-
bradine resulted in a 77% decrease in the frequen-
cy of anginal events (p < 0.001) [7]. The common-
est side effect reported in studies was visual dis-
turbance, which occurred in 14.8% of patients
(Table 2). Borer et al. [6] have also reported that
reduction in HR is greatest in patients with the
highest pre-treatment HR: a unique property of
ivabradine that may minimize the potential for it to
produce excessive bradycardia in selected patients
intolerant to beta-blockers.
The results of the BEAUTIFUL study [8] were
presented at the European Society of Cardiology
2008, where ivabradine was evaluated in addition
to optimal medical therapy. This randomized, dou-
ble-blind, placebo-controlled, parallel-group trial
recruited 10,917 CAD patients with left ventricu-
lar ejection fraction < 40%. Patients received iva-
bradine 5 mg, with the intention of up-titrating to
7.5 mg twice daily (n = 5,479) or placebo (n = 5,438)
on top of recommended guidelines medication.
Most patients were receiving beta-blockade (87%).
Although the primary composite endpoint (cardio-
vascular death, hospitalization for acute MI, or hos-
pitalization for new onset or worsening heart fail-
ure) was not reached for the whole group, it was
beneficial in a pre-specified subgroup of patients
with HR ≥ 70 bpm. The results are very interest-
ing with regards to ‘heart rate’ being considered as
an independent modifiable risk factor for patients
with CAD [8].
Currently, ivabradine is not FDA-approved.
Nicorandil is a nicotinamide ester that has
both nitrate-like vasodilator properties and adeno-
sine triphosphate-potassium channel activating
properties [9] which may offer cardioprotection via
a ‘preconditioning’ effect. Several small randomized
trials have shown nicorandil at a 10 or 20 mg twice
daily dose as prolonging the time to onset of ST-
-segment depression and increasing exercise dura-
tion during stress testing in patients with stable
angina [10, 11].
Nicorandil has also been shown to improve
myocardial perfusion at rest and during  exercise
(Table 2). The preconditioning and possible cardio-
protective effects of nicorandil were investigated in
the Impact of Nicorandil in Angina (IONA) trial [12].
This found a 17% relative risk reduction (p = 0.014)
in the composite primary endpoint of death, non-
-fatal MI and hospitalization. The predominant ad-
verse reactions to treatment reported were head-
aches and gastrointestinal discomfort [12]. More
recently, the efficacy and safety of nicorandil com-
pared to long-acting nitrate has been evaluated in
Chinese patients with stable angina pectoris in
a double-blind, multicenter, active-controlled, ran-
domized clinical trial [13]; 232 patients with stable
angina pectoris were randomized to receive either
nicorandil (5 mg tid; 115 patients) or isosorbide
mononitrate (ISMN: 20 mg bid; 117 patients) for two
weeks. Nicorandil significantly decreased the num-
ber of anginal attacks and nitroglycerine consump-
tion. Both drugs improved the total exercise time
and the time to onset of chest pain on stress test-
Table 2. Pharmacological options for treating refractory angina.
Drug Mechanism of action Site of action Side effect Caution
Ranolazinea Partial fatty Alters Na levels, which Constipation, Other QT
(Ranexa)  oxidation inhibitor through the Na nausea, dizziness, prolonging drugs,
 dependent Ca channels palpitation, hepatic
 prevents Ca overload peripheral edema, dysfunction
    QT prolongation
Ivabradineb Decreases the oxygen Specific inhibitor Visual disturbance Age > 75 years,
(Procorolan)  demand by lowering of I(f) sinoatrial (luminous visual moderately
the heart rate at rest node current phenomenon),  reduced liver
and during exercise bradycardia, headache function
Cr Cl < 15%
Nicorandilb Arterial vasodilator, K channel Headache, Hypotension,
(Ikorel)  venodilator, activator dizziness, flushing with PDE
cardioprotective effect inhibitors
Allopurinol Xanthine oxidase Xanthine oxidase Nausea, diarrhea, Renal
inhibitor  enzyme  hypersensitivity impairment
reactions, rash
aFDA approved; bnot FDA approved, but approved in Europe; Ca — calcium; I(f) — ‘funny’ current; K — potassium; Na — sodium;
PDE — phosphodiesterase
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ing. There was no significant difference between
the two groups, but a trend was noticed towards
more angina relief with nicorandil with equivalent
safety profile. The authors concluded that nicorandil
may have an equal or better anti-anginal effect than
ISMN [13].
Currently, nicorandil is not FDA-approved.
Allopurinol is a xanthine oxidase (XO) inhi-
bitor that has been used for many years in the treat-
ment of gout. It inhibits the XO-catalyzed forma-
tion of uric acid from hypoxanthine and xanthine.
There have been various mechanisms proposed for
the anti-ischemic properties of allopurinol. Allopu-
rinol inhibits XO-derived reactive oxygen species
generation that has been proposed to contribute to
ischemic injury via ATP catabolism during hypoxia
[14–16]. Other proposed mechanisms have been
inhibition of lipid peroxidation [17], heat shock fac-
tor expression [18], calcium sensitizing [19] and the
effect on the antioxidant status of the cells [20].
A recent randomized placebo-controlled crossover
study by Noman et al. [21] demonstrated the pos-
sible role of allopurinol as an effective anti-ische-
mic medication. They enrolled 65 patients with an-
giographically proven CAD who were randomly
assigned to a placebo or allopurinol (600 mg per day)
for six weeks before cross-over. High-dose allopu-
rinol significantly prolonged the time to ST depres-
sion, the total exercise time, and the time to angi-
na in patients with chronic stable angina during
a standard exercise test, suggesting that endoge-
nous xanthine oxidase activity contributes some-
how to exercise-induced myocardial ischemia. The
main side effects were gastrointestinal distress, hy-
persensitivity reactions and skin rash.
Allopurinol has not been FDA-approved for use
as an anti-anginal medication. Clinical guidelines
advocate the use of various drugs to optimize medi-
cal treatment in RAP. However, due to multiple
drug interactions and side effects, this is not always
possible. Hence, investigators have been trying to
explore other non-pharmacological treatment op-
tions.
Non-pharmacological treatments
Enhanced external counterpulsation therapy
The technique of counterpulsation has been
studied for almost half a century now. It is conside-
red a safe, highly beneficial, low-cost, non-invasive
treatment for RAP with or without  left ventricular
dysfunction/heart failure [2]. The technique of
EECP therapy consists of electrocardiogram-gated
rapid, sequential compression of the lower extremi-
ties during diastole, followed by simultaneous de-
compression during systole. These actions produce
hemodynamic effects similar to those of an intra-
aortic balloon pump (IABP). But unlike IABP, EECP
therapy also increases venous return (Fig. 1). A full
course of therapy typically consists of 35 sessions
of one hour per day.
The benefits associated with EECP therapy
include reduction of angina and nitrate use, in-
creased exercise tolerance, favorable psychosocial
effects and enhanced quality of life, prolongation of
the time to exercise-induced ST-segment depres-
sion, and an accompanying resolution of myocardial
perfusion defects.
Recent evidence suggests that EECP therapy
may improve symptoms and decrease long-term
morbidity via more than one mechanism including
improvement in endothelial function, promotion of
collateralization, enhancement of ventricular func-
tion, improvement in oxygen consumption (VO2),
regression of atherosclerosis, and peripheral train-
ing effects similar to exercise [22]. Numerous clini-
cal trials over the last 20 years have shown EECP
therapy to be safe and effective for patients with RAP,
with a clinical response rate averaging 70–80%
(Table 3 [23–27]) which is sustained for up to five
years [28]. It is not only safe in patients with co-
existing heart failure, but has also been shown to
improve quality of life and exercise capacity and to
improve long-term left ventricular function [27, 29,
30]. Side effects include leg or waist pain, skin abra-
sion/ecchymoses, bruises in patients using couma-
din with unadjusted coagulation, paresthesias and
worsening heart failure in patients with severe ar-
rhythmias.
EECP is a treatment modality approved by
the FDA. EECP has a class IIb indication for treat-
ment of RAP as per the 2002 ACC/AHA guidelines.
However, since 2002, there has been significant ac-
cumulation of clinical data supporting EECP thera-
py for positioning in the professional treatment
guidelines with a class IIa rating. This may be the
case in the upcoming ACC/AHA guidelines.
Neurostimulatory techniques
Transcutaneous electrical nerve stimula-
tion (TENS) therapy can ameliorate symptoms in
chronic refractory angina. Essentially, TENS in-
volves applying a low voltage electrical current via
pads placed on the skin in the area of pain. The tech-
nique primarily works via the Gate Control Theory
of Pain. Stimulating large diameter afferent fibers
inhibits input from small diameter fibers in the sub-
stantia gelatinosa of the spinal cord [31]. Another
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Figure 1. Three pairs of pneumatic cuffs are applied to the calves, lower thighs, and upper thighs. The cuffs are
inflated sequentially during diastole, distal to proximal. The compression of the lower-extremity vascular bed incre-
ases diastolic pressure and flow and increases venous return. The pressure is then released at the onset of systole.
Inflation and deflation are timed according to the R-wave on the patient’s cardiac monitor. The pressures applied and
the inflation–deflation timing can be altered by using the pressure waveforms and electrocardiogram on the enhan-
ced external counterpulsation therapy monitor.
Table 3. List of trials.
Authors (reference) Year N Follow-up Angina Nitro use Exercise SPECT
 duration  relief (frequency) capacity  thallium
(%)   (%)  imaging
Various trials of EECP therapy in patients with refractory angina
Lawson et al. [23] 1996 50 35 weeks* Ø(100%) Ø NA ≠(80%)
Arora et al. [24] 1999 139 35 weeks* Ø Ø ≠ NA
Barness et al. [25] 2001 978 35 weeks* Ø(81%) Ø NA ≠(83%)
Fitzgerald et al. [26] 2003 4454 35 weeks* Ø Ø NA NA
Soran et al. [27] 2006 363 35 weeks* Ø(72%) Ø (52%) NA NA
Randomized trials of spinal cord stimulation in patients with refractory angina
Mannheimer et al. [38] 1998 104 NA Ø Ø NA NA
Hautvast et al. [39] 1998 25 NA Ø(41%) Ø(48%) ≠(19%) NA
Greco et al. [40] 1999 517 NA NA NA NA NA
Di Pede et al. [41] 2003 104 NA Ø(73%) NA NA NA
Published trials of laser revascularization in patients with refractory angina
Schofield et al. [43] 1999 79 12 weeks Ø** Ø No change NA
Allen et al. [44] 1999 178 120 days Ø** Ø ≠ Unchanged
Burkhoff et al. [45] 1999 79 12 weeks Ø** Ø ≠ Unchanged
*35 week treatment session; **with associated increase in QOL score; Ødecrease; EECP — enhanced external counterpulsation; ≠increase;
NA — not applicable
commonly held theory for the mechanism of action
of low-frequency TENS is activation of endogenous
opioid pathways. Interestingly, the effect of low fre-
quency (not high frequency) TENS is reversible by
naloxone (an opioid antagonist) [32]. Other mecha-
nisms, such as increased endorphin concentration
in blood and cerebrospinal fluid, have also been pro-
posed [33]. A study by Sanderson [34] showed
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a significant improvement in symptoms and use of
nitroglycerine in a study of 14 patients with RAP.
They demonstrated an increase in the exercise
duration from a mean of 414 ms to 478 ms and
a significant reduction in total ST segment depres-
sion at maximum exercise and 90% controlled HR.
Mannheimer et al. [35] investigated the effects
of TENS with respect to systemic and coronary
hemodynamics and myocardial metabolism in pac-
ing induced angina in a controlled long-term study.
In patients with pacing induced angina, they de-
monstrated an increased tolerance to pacing (142 ±
± 23 compared to 124 ± 20 beats/min tolerated;
p < 0.001), improved lactate metabolism (2 ± 36%
compared to –18 ± 43%; p < 0.01) and less pro-
nounced ST segment depression (2.3 ± 1.1 com-
pared to 2.9 ± 2.6 mm; p < 0.05) with TENS [35].
The benefits of TENS are that it is a passive, non-
-invasive, non-addictive modality with no potentially
harmful side effects.
TENS is currently not approved by the FDA
for the treatment of RAP.
Spinal cord stimulation (SCS) is another
neurostimulatory technique. It is believed that SCS
blocks pain by stimulating the dorsal columns,
which inhibits transmission through the pain-con-
ducting spinothalamic tract [36, 37]. Clinical trials
have investigated the use of SCS for RAP (Table 3
[38–41]). A systematic review by Taylor et al. [42]
that looked at seven randomized controlled trials
evaluating 270 patients, demonstrated SCS to be an
effective and safe treatment option for RAP com-
pared to coronary artery bypass grafting and per-
cutaneous transmyocardial laser revascularization
(PTMLR). Possible benefits include the ease of use
and portability of the device that allows patients to
resume activites at home or at work. The main ad-
verse reactions to SCS are the risk of epidural he-
matoma and infection, occurring in about 1% of pa-
tients. SCS may interfere with the function of pace-
makers and implantable defibrillators by possible
false inhibition of the pacemaker function, but this
risk may be lowered if caution is exercised, such as
programming both devices in bipolar mode, setting
the stimulator frequency to 20 Hz, and performing
the SCS programming under continuous cardiac
monitoring.
SCS is not FDA-approved for RAP treatment,
but has a class IIb indication for treatment of refrac-
tory angina as per ACC/AHA guidelines.
Laser revascularization techniques
Transmyocardial laser revascularization
(TMR/TMLR) has emerged as a novel invasive
treatment for RAP over the last two decades [43].
In this procedure, 20 to 40 transmural channels are
created using a high-energy carbon dioxide laser
with brief manual compression of the epicardial
surface to allow for closure of the epicardial open-
ing sites. Its mechanism of action was initially
thought to be direct perfusion of the myocardium
with the left ventricular blood via these endocar-
dial channels (replicating reptilian circulation).
However, early closure of these channels, and his-
topatholgical studies demonstrating the absence of
true communication between the epicardial chan-
nels and the endocardial cavity,  suggest that this
hypothesis was wrong. It is now thought that the
laser may stimulate angiogenesis and may destroy
nerve fibers to the heart, making patients numb to
their chest pain. Multiple randomized prospective
controlled surgical trials have assessed the safety
and efficacy of TMLR in patients with RAP (Table 3
[43–45]).
Although found to be efficacious in 80% of pa-
tients short-term, there is limited follow-up data to
assess long-term efficacy and freedom from angi-
na. Although investigated initially as a sole therapy
for RAP, it is today mostly used in conjunction with
coronary bypass grafting.
TMR is not approved by the FDA, but has re-




TMR is now being performed percutaneously,
using the less invasive catheter-based approach
percutaneous transmyocardial laser revasculariza-
tion (PTMLR). Oesterle et al. [46] reported the
Potential Angina Class Improvement From In-
tramyocardial Channels (PACIFIC) trial, a multi-
center, randomized study comparing PTMLR in
addition to medical therapy versus medical therapy
alone in 221 patients with CCS class III or IV RAP.
At 12 months, exercise tolerance significantly in-
creased in the PTMLR group, as did anginal class
scores and quality-of-life measurements. Howev-
er, there was no significant difference in overall
mortality. A similar trial by Whitlow et al. [47] com-
pared PTMLR plus medical therapy to medical ther-
apy alone in 330 patients with CCS class II, III or
IV RAP. After 12 months, there was a significant
improvement in anginal class scores, exercise tole-
rance and quality-of-life measures. Again, there
was no difference in one-year survival between the
groups. The results of the DMR In Regeneration
of Endomyocardial Channels Trial (DIRECT) led by
349
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Leon [48] tempered the initial enthusiasm sur-
rounding myocardial laser therapy. This random-
ized, placebo-controlled, prospective trial enrolled
298 patients into three treatment arms: placebo
PTMLR procedure, low-dose PTMLR (10 to 15 cha-
nnels created), or high-dose PTMLR (20 to 25 chan-
nels created). The results were very similar for
treatment arms representing a large ‘placebo effect’
[48]. PTMLR, although popular in the 1990s, has
seen a marked decrease in enthusiasm recently due
to this large placebo effect.
Latest techniques under investigation
Extracorporeal shockwave myocardial
revascularization (ESMR) — this technology
uses low-intensity shockwaves (SW) (one tenth the
strength of those used in lithotripsy) that are de-
livered to myocardial ischemic tissue. Shockwaves,
created by a special generator, are focused using
a shockwave applicator device. The treatment is
guided by standard echocardiography equipment.
The shockwaves are delivered in synchronization
with the patient’s R-wave to avoid arrhythmias. At
first, the patient undergoes stress SPECT testing
to identify the ischemic areas. Following that, the
same area is localized by the ultrasound device and
the shockwaves are focused to the ischemic area
(Fig. 2). Several treatments are required for opti-
mal results.
SW therapy has been demonstrated to induce
localized stress on cell membranes, and to cause
non-enzymatic nitric oxide synthesis from L-argi-
nine and hydrogen peroxide [49]. In pigs, SW thera-
py has been shown to upregulate vascular endo-
thelial growth factor (VEGF) and its receptor, Flt-1,
in endothelial cells in vitro and VEGF in the ischem-
ic myocardium in vivo [50] which is essential in ini-
tiating vasculogenesis and/or angiogenesis. Fuku-
moto et al. [51] demonstrated in a small study of
nine patients with RAP the use of SW therapy. It
improved symptoms, functional class score (CCS)
and reduced nitroglycerine use. The treatment also
improved myocardial perfusion as assessed by dipy-
ridamole stress thallium scintigraphy. SW therapy
has been reported to reduce the frequency and se-
verity of anginal symptoms and to improve exer-
cise tolerance and quality of life [51]. If necessary,
SW therapy can repeatedly be used to treat patients.
Uwatoku et al. [52] demonstrated the suppression
of left ventricular remodeling after acute MI with-
out adverse effects by using SW therapy in an ani-
mal model. This technique is under investigation
and there is a need for more studies, especially pro-
spective randomized studies, to investigate the ef-
fect of SW therapy in patients with RAP.
SW therapy is not yet FDA-approved for the
management and treatment of patients with RAP.
Conclusions
As the mortality from CAD decreases, and the
population ages, an increasing number of patients
will be diagnosed with RAP. This is a problem that
has already attracted the attention of epidemiolo-
gists and provoked interest from researchers and
scientists in investigating new therapies. In the
light of current evidence, ranolazine and enhanced
external counterpulsation therapy have emerged as
more widely accepted modalities in the manage-
ment of patients with RAP.
A multi-disciplinary approach to the care of
these patients will bring better angina relief and
improved quality of life. There is a strong need for
investigators and physicians who can combine these
new treatment modalities to reach the treatment
goals for patients with RAP.
Figure 2. Treatment strategy: at each treatment session, shockwaves are delivered to the border of the ischemic
area. Reproduced with the permission of Gil Hakim of Medispec Ltd.
Session 1 Session 2 Session 3
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